Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, antisense to Neuregulin 2" refers to a natural antisense RNA (NAT) that is transcribed from the opposite DNA strand of the Neuregulin 2 gene (NRG2). NATs are typically non-protein-coding RNAs that can regulate the expression of their corresponding "sense" (protein-coding) gene at multiple levels, including transcription, mRNA stability, alternative splicing, and epigenetic modification. Functional NATs may interact with their sense transcripts or with chromatin to mediate positive or negative regulation of gene expression. Most NATs, including this one, are not direct therapeutic targets, do not encode proteins, and are not classified as receptors, enzymes, or other canonical drug targets. While NATs have emerged as key elements in gene regulation and may have roles in disease through their regulatory functions, there is no specific evidence that this transcript is associated with any human disease, nor are there drugs targeting it directly[1][2][3].
Transcriptional interference RNA masking Epigenetic regulation (e.g., DNA methylation, chromatin modification) Double-stranded RNA (dsRNA)-dependent mechanisms[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to Neuregulin 2 (null).